Shenzhen Hepalink Pharmaceutical Co Ltd Total Liabilities
Shenzhen Hepalink Pharmaceutical Co Ltd total liabilities. Based on the latest financial reports, Shenzhen Hepalink Pharmaceutical Co Ltd (002399) has total liabilities worth CN¥4.78 Billion CNY (≈ $700.04 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check how resilient are Shenzhen Hepalink Pharmaceutical Co Ltd's assets to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Shenzhen Hepalink Pharmaceutical Co Ltd (2006–2025)
Total liabilities of Shenzhen Hepalink Pharmaceutical Co Ltd from 2006 to 2025. This chart illustrates how Shenzhen Hepalink Pharmaceutical Co Ltd's total liabilities have evolved over time, based on quarterly financial data.
Shenzhen Hepalink Pharmaceutical Co Ltd Competitors by Total Liabilities
The table below lists competitors of Shenzhen Hepalink Pharmaceutical Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Marqeta Inc
NASDAQ:MQ
|
USA | $676.67K |
|
RLJ Lodging Trust
NYSE:RLJ
|
USA | $3.07 Billion |
|
Focus Technology Co Ltd
SHE:002315
|
China | CN¥1.91 Billion |
|
Solvac S.A.
BR:SOLV
|
Belgium | €215.41 Million |
|
Gansu Qilianshan Cement Group Co Ltd
SHG:600720
|
China | CN¥14.30 Billion |
|
Farasis Energy Gan Zhou Co Ltd
SHG:688567
|
China | CN¥14.89 Billion |
|
Lier Chemical Co Ltd
SHE:002258
|
China | CN¥7.88 Billion |
|
Qingdao Huicheng Environmental Co Ltd
SHE:300779
|
China | CN¥4.76 Billion |
Liability Composition Analysis (2006–2025)
This chart breaks down Shenzhen Hepalink Pharmaceutical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see 002399 current and non-current assets.
Liquidity & Leverage Metrics
Shenzhen Hepalink Pharmaceutical Co Ltd Total Liabilities Ratios Explained
Shenzhen Hepalink Pharmaceutical Co Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.15 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.39 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.28 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Shenzhen Hepalink Pharmaceutical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Shenzhen Hepalink Pharmaceutical Co Ltd (2006–2025)
The table below shows the annual total liabilities of Shenzhen Hepalink Pharmaceutical Co Ltd from 2006 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥4.55 Billion ≈ $666.04 Million |
-11.47% |
| 2024-12-31 | CN¥5.14 Billion ≈ $752.35 Million |
-28.74% |
| 2023-12-31 | CN¥7.22 Billion ≈ $1.06 Billion |
-14.17% |
| 2022-12-31 | CN¥8.41 Billion ≈ $1.23 Billion |
+10.83% |
| 2021-12-31 | CN¥7.58 Billion ≈ $1.11 Billion |
+3.38% |
| 2020-12-31 | CN¥7.34 Billion ≈ $1.07 Billion |
-5.59% |
| 2019-12-31 | CN¥7.77 Billion ≈ $1.14 Billion |
+4.87% |
| 2018-12-31 | CN¥7.41 Billion ≈ $1.08 Billion |
+34.66% |
| 2017-12-31 | CN¥5.50 Billion ≈ $805.23 Million |
+14.05% |
| 2016-12-31 | CN¥4.83 Billion ≈ $706.06 Million |
+42.95% |
| 2015-12-31 | CN¥3.38 Billion ≈ $493.93 Million |
+113.93% |
| 2014-12-31 | CN¥1.58 Billion ≈ $230.88 Million |
+674.17% |
| 2013-12-31 | CN¥203.80 Million ≈ $29.82 Million |
-5.00% |
| 2012-12-31 | CN¥214.53 Million ≈ $31.39 Million |
+257.69% |
| 2011-12-31 | CN¥59.98 Million ≈ $8.78 Million |
-42.02% |
| 2010-12-31 | CN¥103.44 Million ≈ $15.14 Million |
-66.23% |
| 2009-12-31 | CN¥306.33 Million ≈ $44.83 Million |
+13.00% |
| 2008-12-31 | CN¥271.09 Million ≈ $39.67 Million |
+143.60% |
| 2007-12-31 | CN¥111.28 Million ≈ $16.28 Million |
-56.81% |
| 2006-12-31 | CN¥257.68 Million ≈ $37.71 Million |
-- |
About Shenzhen Hepalink Pharmaceutical Co Ltd
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. provides pharmaceutical products in Hong Kong, the United States, Europe, Mainland China, and internationally. It operates in four segments: Pharmaceutical preparations, Active Pharmaceutical Ingredients (API), Contract Development and Manufacturing Organization (CDMO), and Others. The company offers pharmaceutical preparations products, such as en… Read more